This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Campus
  1. Resource
  2. Source: Campus Sanofi
  3. 23 Oct 2023

Praluent® (alirocumab) Patient profiles

Author: Sanofi

Editorial Team

Praluent logo

Prescribing Information(GB)

Prescribing Information(NI)

Second MI

6 weeks ago

Age: 55 years
LDL-C: 3.6 mmol/L 
Polyvascular disease  (CAD & PAD) 
Smoker

Praluent Patient Profile 1

First MI

6 months ago

Age: 63 years
LDL-C: 4.1 mmol/L
No additional comorbidities or family history of heart disease
Non-smoker

Praluent Patient Profile 3

First MI

12 months ago

Age: 63 years
LDL-C: 5.0 mmol/L
Familial hypercholesterolaemia 
Non-smoker

Praluent Patient Profile 2

Any ACS means the patient is at very high CV risk, regardless of comorbidities1

SEE MORE FROM SCIENCE

Praluent®

Find more information on Indication, Administration and Mechanism of Action and watch videos about Praluent®.

Patient Website

Find resources and support for your patients on Praluent®. Find useful links about how patients can manage their cholesterol.

Get in touch with the Dyslipidaemia Team
MAT-XU-2201545 (v5.0) Date of Preparation: October 2023
References
  1. March F, et al.2019 ESC/EAS Guidelines for the management of dyslipidaemias; lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111-188.

MAT-XU-2204602 (v7.0) Date of Preparation: February 2024